Cytokinetics, Incorporated (CYTK): Price and Financial Metrics

Cytokinetics, Incorporated (CYTK): $53.93

1.22 (+2.31%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

C

Add CYTK to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#212 of 351

in industry

CYTK Price/Volume Stats

Current price $53.93 52-week high $110.25
Prev. close $52.71 52-week low $25.98
Day low $51.87 Volume 1,182,800
Day high $54.35 Avg. volume 2,751,224
50-day MA $60.84 Dividend yield N/A
200-day MA $55.30 Market Cap 5.65B

CYTK Stock Price Chart Interactive Chart >


Cytokinetics, Incorporated (CYTK) Company Bio


Cytokinetics, Incorporated, a clinical stage biopharmaceutical company, focuses on the discovery and development of novel small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. The company was founded in 1997 and is based in South San Francisco, California.


CYTK Latest News Stream


Event/Time News Detail
Loading, please wait...

CYTK Latest Social Stream


Loading social stream, please wait...

View Full CYTK Social Stream

Latest CYTK News From Around the Web

Below are the latest news stories about CYTOKINETICS INC that investors may wish to consider to help them evaluate CYTK as an investment opportunity.

Cytokinetics Stock Jumps To Higher RS Level; Shoots Up On Heart Drug Study

On Thursday, Cytokinetics cleared a key performance benchmark, with its Relative Strength (RS) Rating entering into the 90-plus percentile with an improvement to 99, an increase from 89 the day before. The clinical-stage biotech company shot up 83% on Wednesday after announcing positive results from a Phase 3 study of its experimental drug to treat heart disease. The drug, Aficamten, which treats symptomatic obstructive hypertrophic cardiomyopathy (HCM) is a contender to challenge Bristol Myer Squibb's Camzyos drug.

Yahoo | December 28, 2023

Cytokinetics (CYTK) Up 83% as Cardiomyopathy Drug Meets Goals

Cytokinetics (CYTK) reports positive results from its pivotal late-stage study of aficamten in symptomatic obstructive hypertrophic cardiomyopathy patients. The stock rallies 83% in response.

Yahoo | December 28, 2023

Biotech Stock Roundup: BMY's KRTX and RYZB Acquisition, CYTK Surges on Study Data

Bristol Myers (BMY) and Cytokinetics (CYTK) are in the news on acquisition announcements and study updates, respectively.

Yahoo | December 28, 2023

Company News for Dec 28, 2023

Companies In The Article Are:CYTK,TSLA, NYT, MSFT, IOVA

Yahoo | December 28, 2023

Stocks Static As Post-Holiday Doldrums Hit

Stocks are struggling for direction today, as the post-holiday doldrums take full effect.

TalkMarkets.com | December 27, 2023

Read More 'CYTK' Stories Here

CYTK Price Returns

1-mo -10.00%
3-mo -17.27%
6-mo 49.43%
1-year 54.79%
3-year 147.50%
5-year 401.67%
YTD -35.41%
2023 82.21%
2022 0.53%
2021 119.35%
2020 95.85%
2019 67.88%

Continue Researching CYTK

Want to see what other sources are saying about Cytokinetics Inc's financials and stock price? Try the links below:

Cytokinetics Inc (CYTK) Stock Price | Nasdaq
Cytokinetics Inc (CYTK) Stock Quote, History and News - Yahoo Finance
Cytokinetics Inc (CYTK) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!